A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

HealthDay News — For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes, according to a study ...

The list of benefits for Novo Nordisk's semaglutide keeps getting longer ... City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), compared to an 8.7 reduction with placebo.

On the other hand, BioPharmaDive notes that the pill Novo wants FDA approval for contains 70 times as much semaglutide as injectable Ozempic. The journal points out that such a large increase in ...

The Danish pharma company has filed 320 patent applications for its three semaglutide drugs and has been granted 154, according to I-MAK. Its main patent for semaglutide is set to expire at the ...

Interest in weight-loss products continues to surge as calls come for a faster rollout of treatments on the NHS. Research by ...

Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...

it should leave LLY well-positioned to take share from semaglutide and further grow the market with an oral approach,” analyst Gould adds. Cantor writes that Eli Lilly could have an over 85% ...